桂枝茯苓丸对更年期综合征影响的随机对照预试验研究方案
本研究为单中心、随机、安慰剂对照、平行组设计预试验,计划纳入50例更年期综合征女性,按1:1随机分配至桂枝茯苓丸组或安慰剂组,每日三次服用颗粒剂共4周,随后随访4周。主要结局为随机化后5周时更年期评定量表评分平均变化,次要结局包括世界卫生组织生活质量-BREF评分、气上冲与下腹抵抗及压痛程度、血瘀证问卷评分及血脂、超敏C反应蛋白、促卵泡激素、雌二醇等血液检测结果。
要点
- 干预为桂枝茯苓丸或安慰剂颗粒每日三次共4周,随后随访4周。
- 主要结局为随机化后5周时更年期评定量表评分平均变化。
核心结论
- 本研究结果将为设计评价桂枝茯苓丸治疗女性更年期综合征疗效的大规模临床试验提供基础数据。
研究设计与样本
- 单中心、随机、安慰剂对照、平行组设计预试验,计划纳入50例更年期综合征女性,按1:1随机分配至桂枝茯苓丸组或安慰剂组。
关键数值与推荐
- 主要结局为随机化后5周时更年期评定量表评分平均变化。
- 次要结局包括世界卫生组织生活质量-BREF评分、气上冲与下腹抵抗及压痛程度、血瘀证问卷评分及血液检测结果(血脂、超敏C反应蛋白、促卵泡激素、雌二醇)。
- 可行性结局包括招募率、完成率和服药依从性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study is to explore the efficacy of Guizhifulingwan (GFW) in the treatment of climacteric syndrome in women. METHODS/DESIGN: This is a single-center, randomized, placebo-controlled, parallel-group design pilot trial. Fifty participants with climacteric syndrome will be randomly allocated to the GFW or placebo group in a 1:1 ratio. The participants will be administered GFW or placebo granules three times a day for 4 weeks and will be followed up for a further 4 weeks. The primary outcome is the mean change in menopause rating scale score at 5 weeks after randomization. Secondary outcomes include the World Health Organization quality of life-BREF scores, degrees of upward movement of qi and lower abdominal resistance and tenderness, blood stasis pattern questionnaire scores, and results of blood tests including assays for lipid profile, high sensitivity C-reactive protein, follicle-stimulating hormone, and estradiol. The feasibility outcomes include recruitment and completion rates and adherence to medication. DISCUSSION: The results of this study will provide basic data for the design of a large-scale clinical trial for evaluating the efficacy of GFW in the treatment of climacteric syndrome in women. TRIAL REGISTRATION: Clinical Research Information Service (CRIS), Republic of Korea, KCT0002040 . Registered on 5 September 2016.
引用
- Kim JE, Cho J, Kwon O, et al. Effect of Guizhifulingwan (Keishibukuryogan) on climacteric syndrome: study protocol for a randomized controlled pilot trial. Trials. 2017. PMID: 28327172. doi:10.1186/s13063-017-1877-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。